[{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AKR-001","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AKR-001","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"AKR-001","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Financing","leadProduct":"Efruxifermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.029999999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Pfizer Inc","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Pfizer Inc"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"FGF21","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Efruxifermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.37,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Public Offering","leadProduct":"Efruxifermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0.20000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.37,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Efruxifermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.37,"dosageForm":"Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Efruxifermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0.32000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.37,"dosageForm":"Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Public Offering","leadProduct":"Efruxifermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0.37,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.37,"dosageForm":"Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Efruxifermin","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Akero Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21R","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21R","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Efruxifermin","moa":"FGF21R","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0.29999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.40000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Efruxifermin","moa":"FGF21R","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.40000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Public Offering","leadProduct":"Efruxifermin","moa":"FGF21R","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0.40000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.40000000000000002,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ J.P. Morgan","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ J.P. Morgan"},{"orgOrder":0,"company":"Akero Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"Efruxifermin","moa":"FGF21R","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Akero Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Akero Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Akero Therapeutics \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals by Akero Therapeutics
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
